Cambrex Corp. (NYSE:CBM) – Research analysts at Craig Hallum issued their Q1 2017 earnings estimates for Cambrex Corp. in a research report issued to clients and investors on Monday. Craig Hallum analyst M. Tiampo anticipates that the brokerage will post earnings per share of $0.48 for the quarter. Craig Hallum also issued estimates for Cambrex Corp.’s Q2 2017 earnings at $0.71 EPS, Q3 2017 earnings at $0.52 EPS and Q4 2017 earnings at $1.20 EPS.

CBM has been the topic of a number of other reports. Zacks Investment Research raised Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $53.00 target price on the stock in a research report on Monday. First Analysis raised Cambrex Corp. from an “equal weight” rating to an “overweight” rating and set a $54.00 target price on the stock in a research report on Monday.

Earnings History and Estimates for Cambrex Corp. (NYSE:CBM)

Shares of Cambrex Corp. (NYSE:CBM) opened at 50.95 on Thursday. Cambrex Corp. has a 12 month low of $29.50 and a 12 month high of $59.41. The stock’s 50 day moving average price is $43.61 and its 200-day moving average price is $47.60. The firm has a market capitalization of $1.64 billion, a PE ratio of 25.76 and a beta of 1.81.

Cambrex Corp. (NYSE:CBM) last announced its quarterly earnings results on Friday, November 4th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.06. The business had revenue of $99.90 million for the quarter, compared to analysts’ expectations of $96.07 million. Cambrex Corp. had a return on equity of 24.11% and a net margin of 13.24%. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.40 EPS.

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new stake in Cambrex Corp. during the second quarter worth $106,000. BlackRock Inc. increased its stake in Cambrex Corp. by 3.4% in the third quarter. BlackRock Inc. now owns 2,951 shares of the company’s stock worth $131,000 after buying an additional 96 shares during the last quarter. Acrospire Investment Management LLC increased its stake in Cambrex Corp. by 149.0% in the second quarter. Acrospire Investment Management LLC now owns 2,674 shares of the company’s stock worth $138,000 after buying an additional 1,600 shares during the last quarter. Intrust Bank NA bought a new stake in Cambrex Corp. during the second quarter worth $206,000. Finally, PineBridge Investments L.P. increased its stake in Cambrex Corp. by 4.4% in the second quarter. PineBridge Investments L.P. now owns 4,056 shares of the company’s stock worth $210,000 after buying an additional 171 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Cambrex Corp. Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

5 Day Chart for NYSE:CBM

Receive News & Stock Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related stocks with our FREE daily email newsletter.